
Pfizer PFE
Annual report 2025
added 02-26-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
5.68 B |
Market Cap[1] |
$ 155 B |
EBITDA (LTM) |
$ 6.66 B |
P/E (LTM) |
11.14 |
P/S (LTM) |
2.46 |
EPS (LTM) |
2.44 |
Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.
Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.
In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.
Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.
As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Burford Capital Limited
BUR
|
$ 4.73 | 0.42 % | $ 761 M | NYSE | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 333.39 | -1.77 % | $ 43.7 B | Nasdaq Global Select Market,SPB | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 3.17 | 3.93 % | $ 5.22 M | NYSE American | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.73 | 3.04 % | $ 8.97 B | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aligos Therapeutics
ALGS
|
$ 7.42 | -15.1 % | $ 73.3 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 21.68 | 1.4 % | $ 1.01 B | Nasdaq Global Select Market | ||
|
Cabaletta Bio
CABA
|
$ 3.4 | 4.29 % | $ 342 M | Nasdaq Global Select Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 99.47 | 1.08 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
- | - | $ 399 M | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Aquestive Therapeutics
AQST
|
$ 4.24 | 2.17 % | $ 453 M | Nasdaq Global Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.58 | -2.03 % | $ 3.13 B | Nasdaq Global Select Market,SPB | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.49 | 0.68 % | $ 397 M | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 33.87 | 1.62 % | $ 2.25 B | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.